Compare MobilEye Global Inc (MBLY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MobilEye Global Inc vs Recursion Pharmaceuticals Inc — how do they compare? MobilEye Global Inc trades at $7.07 (market cap $6.08B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.31B). The key difference: MobilEye Global Inc is far larger — about 2.6× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MobilEye Global Inc for 15 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| MBLY | RXRX | |
|---|---|---|
Market Cap | $6.08B | $2.31B |
Volume | 4,250,290 | 40,478,768 |
Sector | Consumer Cyclical | Health |
52-Week High | $15.42 | $6.79 |
52-Week Low | $6.56 | $2.84 |
Typical Hold Time | 15 Days | 22 Days |
Enterprise Value | $4.64B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mobileye Global (MBLY) trades at $7.15, down 4.28% amid bearish technical signals, though RSI levels suggest potential oversold conditions. The company shows mixed fundamentals with strong revenue growth to $2.0B in 2026 but deep losses (-$4.1B net income). Analyst consensus remains positive with 57.7% buy ratings and $10.83 price target, while recent news highlights ADAS business momentum and autonomous vehicle expansion initiatives.
MBLY presents a high-risk opportunity with significant upside potential if execution improves, but current profitability challenges and bearish technicals warrant caution. The stock trades below book value (P/B 0.74) with institutional confidence shown through recent insider buying, though competitive pressures in autonomous driving and ongoing losses represent substantial investor risks.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
